Paul Isaac
Arbiter Partners Capital Management
Paul Isaac Paratek Pharmaceuticals Inc stake
total: 298
Arbiter Partners Capital Management PRTK trades
- Total transactions:
- 8
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 3
- Held since:
- 2018 Q1
- Held for:
- 9 quarters
- Latest activity:
- 2020 Q2
According to 2026 Q2 report, Paul Isaac doesn't hold any Paratek Pharmaceuticals Inc (PRTK) shares. To date, the estimated cost basis is nearly $9.79 for "buy" trades and estimated average "sell" price is $3.36. Arbiter Partners Capital Management first purchased PRTK in 2018 Q1, initially acquiring 93,350 shares. Since the initial investment in Paratek Pharmaceuticals Inc (PRTK), Arbiter Partners Capital Management has made 7 more transactions.
When did Paul Isaac sell Paratek Pharmaceuticals Inc (PRTK)?
Paul Isaac sold off the entire Paratek Pharmaceuticals Inc (PRTK) position in 2020 Q2.
When did Paul Isaac buy Paratek Pharmaceuticals Inc (PRTK)?
Paul Isaac first invested in Paratek Pharmaceuticals Inc (PRTK) in 2018 Q1 at the reported quarter-end price of $13.00 per share.
What's the cost basis of Arbiter Partners Capital Management's PRTK stake?
The estimated cost basis for Paratek Pharmaceuticals Inc (PRTK) stake is around $9.79 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $9.79
- Weighted AVG sell price:
- $3.36
Paul Isaac's historical trades in Paratek Pharmaceuticals Inc
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2020 Q2
|
0.00%
|
$3.15
|
-100% (-193,124)
|
|||
|
2020 Q1
|
0.72%
|
$3.15
|
-77.23% (-654,945)
|
|||
|
2019 Q4
|
2.71%
|
$4.03
|
-23.35% (-258,353)
|
|||
|
2019 Q1
|
4.67%
|
$5.36
|
-0.50% (-5,514)
|
|||
|
2018 Q4
|
3.28%
|
$5.13
|
+12.07% (+119,790)
|
|||
|
2018 Q3
|
3.58%
|
$9.70
|
+27.80% (+215,837)
|
|||
|
2018 Q2
|
3.03%
|
$10.20
|
+731.61% (+682,959)
|
|||
|
2018 Q1
|
0.41%
|
$13.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.